Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rejuvel Bio-Sciences, Inc. (NUUU)
Miami, FL, US
Rejuvel Bio-Sciences, Inc. is a development-stage firm operating globally, primarily involved in the production, distribution, and marketing of skincare products. Its main offering is a skin cream sold under the Rejuvel brand. Additionally, the company intends to develop and commercialize environmental management systems that employ electron particle accelerator technology for the purification of drinking water, the treatment of municipal and industrial wastewater and sludge, and the processing of produced water from oil and gas fracturing activities. The company, which was previously known as Technology Applications International Corporation, officially changed its name to Rejuvel Bio-Sciences, Inc. in June 2015. Founded in 2009, Rejuvel Bio-Sciences maintains its headquarters in Miami, Florida.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +9,900.00% | +0.00% | +0.00% | +9,900.00% | +0.00% | +900.00% | +0.00% | -87.50% | -90.91% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Household & Personal Products: +3.3%+82.5% ★ Q3'15: +174.7% (vs Q3'14)
-
EPS growth Household & Personal Products: +8.8%+63.0% ★ Q3'15: -725.0% (vs Q3'14)
-
FCF margin FCF growth · Household & Personal Products: +44.8%-152.4% Q3'15: -184.4% (vs Q3'14)
-
EBIT margin Household & Personal Products: +9.9%-270.1% Q3'15: -401.4% (vs Q3'14)
-
ROIC Household & Personal Products: +8.2%— Q3'15: +66.8% (vs Q3'14)
-
Share dilution Household & Personal Products: +0.2%-19.4% ★ Q3'15: -52.2% (vs Q3'14)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×-0.63× Q3'15: -0.45× (vs Q3'14)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | D&E Global Management, Inc. EIN #65-1152410 | 4.35M | 8.60% | 4.35M | — | 4.35M | — | CO | Florida | 2015-08-19 | ↗ |
| 2 | International Consulting & Equity Group, Inc. EIN# 45-3704272 | 3.88M | 7.60% | 3.88M | — | 3.88M | — | CO | Florida | 2015-08-19 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Charles J. Scimeca | Chief Executive Officer & Director | 120.0K | male |
| David Pollock | President of Zero Gravity Sciences, Inc | — | male |
| Matthew J. Cohen | Chief Financial Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NUUU
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
